This double-blind, randomised controlled trial (n=200) aims to evaluate the attitudes of Australian psychologists, psychiatrists, and mental health researchers towards MDMA-assisted psychotherapy for the treatment of PTSD.
Online, parallel-group randomized vignette study recruiting Australian psychologists, psychiatrists and mental health researchers who read a single vignette describing a hypothetical Phase 3 trial of either MDMA-assisted psychotherapy or a fabricated drug (JB-4801) plus psychotherapy.
Participants complete a ~10-minute survey (one timepoint between February and November 2020) with outcomes including subjective safety concern (10-point Likert) and predicted efficacy (10-point Likert). No direct contact or actual drug administration occurs.
Online vignette describing MDMA-assisted psychotherapy (hypothetical Phase 3 trial).
Participant reads a vignette describing MDMA-assisted psychotherapy; no actual dosing.
Online vignette describing a fabricated JB-4801-assisted psychotherapy (control).
Fabricated compound 'JB-4801' used in vignette to avoid prior beliefs; no actual dosing.